How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
Big Pharma is rethinking industrial heat as more than a factory utility. It is becoming a strategic asset for cost control, energy security, supply-chain resilience, and emissions reduction.
Why Industrial Heat Matters In Pharmaceutical Manufacturing
Pharmaceutical production depends heavily on heat. Research labs, active ingredient plants, formulation sites, sterilization lines, and packaging facilities all need reliable thermal energy. For years, this heat was treated as a basic operating cost, often supplied by fossil gas, boilers, combined heat and power systems, or other conventional sources.
That view is changing. As energy prices fluctuate and climate rules tighten, pharmaceutical companies are realizing that the way they generate and manage heat can affect margins, reputation, regulatory readiness, and long-term competitiveness.
The shift is clear in AstraZenecaâs Clean Heat Program, developed with ERM and Secaro. The initiative is designed to help companies and suppliers move from emissions reporting to real industrial heat decarbonization projects. ERM says the program combines supply-chain data, technical expertise, and implementation support to help suppliers overcome practical barriers to low-carbon heat.
AstraZenecaâs Clean Heat Program Signals A Bigger Industry Shift
AstraZeneca has positioned clean heat as part of its wider climate strategy. The companyâs Ambition Zero Carbon targets include reducing absolute Scope 1 and Scope 2 greenhouse gas emissions by 98% by 2026 from a 2015 baseline, and reducing Scope 3 emissions by 35% by 2030 from a 2019 baseline.
This matters because Scope 3 emissions often come from suppliers, logistics, materials, and the broader value chain. In the pharmaceutical industry, that value chain can be complex, global, and energy-intensive. A company may reduce emissions at its own factories, but still face major climate exposure if its suppliers depend on high-carbon heat.
The Clean Heat Program focuses on this difficult problem. Secaro describes it as a joint initiative from Secaro and ERM, with AstraZeneca as sponsor, designed to help customers and suppliers move from reporting to delivery.
From Sustainability Goal To Business Strategy
The key change is that clean heat is no longer only an environmental topic. It is becoming a business strategy. Pharmaceutical companies need stable production, predictable energy costs, trusted suppliers, and proof that their operations can meet future climate expectations.
Industrial heat decarbonization can support all of those goals. A factory that uses renewable electricity, biomethane, heat pumps, thermal storage, or other low-carbon systems may reduce its exposure to fossil fuel price swings. It may also become better prepared for carbon pricing, climate disclosure rules, and customer pressure.
For large drugmakers, this is especially important because medicine supply chains must be dependable. Interruptions can affect hospitals, patients, pharmacies, and national health systems. If clean heat improves resilience, it becomes part of risk management, not just corporate responsibility.
Why Heat Is Harder To Decarbonize Than Electricity
Many companies have already made progress buying renewable electricity. Heat is harder. Industrial heat often needs specific temperatures, steady output, strict safety standards, and integration with existing equipment. A boiler cannot always be replaced overnight without affecting production quality or regulatory compliance.
That is why implementation support matters. Suppliers may know they need to cut emissions, but they may not know which technology fits their site. They may lack financing, engineering support, reliable data, or confidence that a project will pay off.
ERM has said the Clean Heat Program aims to help projects that often get stuck after early assessment. That is important because many decarbonization plans fail not because the idea is bad, but because the path from study to construction is unclear.
Biomethane, Renewable Energy, And Practical Solutions
AstraZeneca has also used biomethane as one clean heat pathway. In 2025, Reuters reported that AstraZeneca opened a UK biomethane plant through a 15-year partnership with Future Biogas. The plant was expected to supply 100 gigawatt hours of renewable energy per year to UK research, development, and manufacturing sites.
Biomethane is not the only option. Depending on the site, companies may consider electric boilers, industrial heat pumps, renewable natural gas, green hydrogen in limited cases, waste heat recovery, thermal batteries, solar thermal systems, or hybrid designs. The best choice depends on temperature needs, local energy prices, grid reliability, available fuels, and capital cost.
This is why a data-based program can be useful. Instead of giving every supplier the same solution, companies can map sites, identify heat demand, compare options, estimate cost, and prioritize projects with the strongest business case.
Why Big Pharma Cares About Supplier Heat
Pharmaceutical companies rely on thousands of suppliers. These suppliers may produce chemicals, packaging, ingredients, lab materials, devices, and logistics services. Many of them use heat every day.
If suppliers run on fossil fuels, those emissions become part of the pharmaceutical companyâs value-chain footprint. As investors, regulators, and customers ask for better Scope 3 data, drugmakers need more than estimates. They need real reductions.
The Clean Heat Program is built around supplier engagement at scale. Secaro says its platform supports supplier data collection, site-level analysis, and reporting.
Clean Heat As A Competitive Advantage
Clean heat can give pharmaceutical companies several advantages. First, it can lower carbon exposure. Second, it can reduce dependence on volatile fossil fuels. Third, it can strengthen supplier relationships by helping smaller firms solve technical problems. Fourth, it can support product-level sustainability claims, which may matter more in healthcare procurement over time.
Hospitals and health systems are under pressure to reduce their own climate impact. If they begin favoring lower-carbon medicines, packaging, and suppliers, pharmaceutical companies with cleaner manufacturing networks may gain an edge.
This does not mean clean heat is easy. Projects can be expensive, site-specific, and slow. But the strategic logic is becoming stronger. Energy is no longer just a bill. It is part of business continuity, climate credibility, and market access.
The Bigger Message For The Pharmaceutical Sector
The Forbes report highlights a wider trend: industrial heat is moving from the background of pharmaceutical operations to the center of strategic planning. The issue is not just how factories stay warm or power production lines. It is how drugmakers build resilient, low-carbon, future-ready supply chains.
For Big Pharma, the next stage of climate action will likely be more practical and operational. Companies will need to identify heat sources, work with suppliers, unlock financing, choose proven technologies, and measure actual results.
AstraZenecaâs approach shows that the sector is beginning to treat heat as a value lever. When managed well, industrial heat can reduce emissions, protect operations, support suppliers, and create a stronger foundation for long-term growth.
Conclusion
Big Pharmaâs clean heat push shows how climate strategy is becoming industrial strategy. The sector cannot meet ambitious emissions goals through renewable electricity alone. It must also address the heat used across research, development, manufacturing, and supply chains.
AstraZenecaâs Clean Heat Program, backed by ERM and Secaro, is an example of how companies can turn a difficult emissions challenge into a practical business opportunity. By treating industrial heat as a strategic asset, pharmaceutical companies can improve resilience, manage costs, reduce risk, and prepare for a lower-carbon future.
#SlimScan #GrowthStocks #CANSLIM